Treatment of Hypertrophic Scars Using Laser and Laser Assisted Corticosteroid Delivery

Lasers in Surgery and Medicine 45:135–140 (2013)
Treatment of Hypertrophic Scars Using Laser
and Laser Assisted Corticosteroid Delivery
Jill S. Waibel, MD,1 Adam J. Wulkan, BS,2 and Peter R. Shumaker, MD3
1
Miami Dermatology, Laser Institute, Miami, Florida 33173
2
University of Miami Miller School of Medicine, Miami, Florida 33136
3
Department of Dermatology Naval Medical Center, San Diego, California, 92134
Background and Objectives: Hypertrophic scars and
contractures are common following various types of trauma and procedures despite skilled surgical and wound
care. Following ample time for healing and scar maturation, many millions of patients are burdened with persistent symptoms and functional impairments. Cutaneous
scars can be complex and thus the approach to therapy is
often multimodal. Intralesional corticosteroids have long
been a staple in the treatment of hypertrophic and restrictive scars. Recent advances in laser technology and applications now provide additional options for improvements
in function, symptoms, and cosmesis. Fractional ablative
lasers create zones of ablation at variable depths of the
skin with the subsequent induction of a wound healing
and collagen remodeling response. Recent reports suggest
these ablative zones may also be used in the immediate
post-operative period to enhance delivery of drugs and
other substances. We present a case series evaluating the
efficacy of a novel combination therapy that incorporates
the use of an ablative fractional laser with topically applied triamcinolone acetonide suspension in the immediate post-operative period.
Methods: This is a prospective case series including 15
consecutive subjects with hypertrophic scars resulting
from burns, surgery or traumatic injuries. Subjects were
treated according to typical institutional protocol with
three to five treatment sessions at 2- to 3-month intervals
consisting of fractional ablative laser treatment and
immediate post-operative topical application of triamcinolone acetonide suspension at a concentration of 10
or 20 mg/ml. Three blinded observers evaluated
photographs taken at baseline and six months after the
final treatment session. Scores were assigned using a
modified Manchester quartile score to evaluate enhancements in dyschromia, hypertrophy, texture, and overall
improvement.
Limitations: Small sample size and lack of a control
arm.
Results: Combination same session laser therapy and immediate post-operative corticosteroid delivery resulted in
average overall improvement of 2.73/3.0. Dyschromia
ß 2013 Wiley Periodicals, Inc.
showed the least amount of improvement while texture
showed the most improvement.
Conclusion: Combination same-session therapy with ablative fractional laser-assisted delivery of triamcinolone
acetonide potentially offers an efficient, safe and effective
combination therapy for challenging hypertrophic and
restrictive cutaneous scars. Lasers Surg. Med. 45:135–
140, 2013. ß 2013 Wiley Periodicals, Inc.
Key words: drug delivery systems; fractional laser;
hypertrophic scar; scar therapy; triamcinolone acetonide;
laser assisted delivery systems
INTRODUCTION
The unprecedented survival of individuals who sustain
acute burns and other trauma both on and off the battlefield has increased the necessity for effective modalities in
the treatment and rehabilitation of patients [1]. Due to a
complex interplay of factors such as injury mechanism
and tissue tension, elevated levels of IL-4 and other procollagen cytokines may result in a net excess of collagen
contributing to the newly formed hypertrophic scar [2].
Treating severe cutaneous scars is complex, and despite
the best surgical care and adequate healing time, many
millions of patients continue to have functional impairments and symptoms such as burning, itching, and pain.
When treating hypertrophic scars, both functional and
aesthetic improvement is the ultimate goal. Multiple therapeutic options have previously been described including
surgical revision, laser therapy, pressure therapy, silicone
The views expressed in this article are those of the authors and
do not necessarily reflect the official policy or position of the
Department of the Navy, Department of Defense, or the United
States Government.
Conflict of Interest Disclosures: All authors have completed
and submitted the ICMJE Form for Disclosure of Potential
Conflicts of Interest and none were reported.
*Corresponding to: Jill S. Waibel, MD, Miami Dermatology &
Laser Institute, 7800 SW 87th Avenue, Miami, FL 33173.
Accepted 31 January 2013
Published online 4 March 2013 in Wiley Online Library
(wileyonlinelibrary.com).
DOI 10.1002/lsm.22120
136
WAIBEL ET AL.
gel sheets, intralesional injections, pressure garments,
and adjuvant topical drug treatments [3–8]. Successful
outcomes have been achieved with vascular-specific lasers
when treating severe hypertrophic scars [9–11]. Alster
first reported improvement after two treatments with
pulsed dye lasers for hypertrophic surgical and traumatic
scars. The authors also noted reductions in erythema, elevation, itching, and pain [12].
Fractional lasers were developed within the last decade
and have mainly been applied to cosmetic indications
such as the mitigation of rhytides [13,14]. However, there
is increasing evidence that fractional lasers are an emerging therapeutic option for the aesthetic restoration and
functional enhancement of traumatic scars at virtually
any location on the body [14–18]. Fractional lasers create
zones of ablation at variable depths determined by the
treatment settings. The unique fractional injury induces
a molecular cascade including heat shock proteins and
other factors that lead to a rapid healing response and
prolonged neocollagenesis with subsequent collagen
remodeling [14]. The mechanism of improvement after ablative fractional laser therapy therefore likely includes
the removal of a portion of fibrotic scar and a relative normalization of collagen structure and composition [19].
Intralesional steroid injections are a well-recognized
treatment for hypertrophic scars. The procedure involves
a uniform injection of 10–40 mg/ml of triamcinolone acetonide suspension with a 25- to 27-gauge needle [20]. One
of the long-standing challenges of using intralesional corticosteroid for scar therapy is precise placement of the
drug to avoid adverse sequelae such as fat atrophy. In
their report on management of hypertrophic scars and
keloids, Mustoe et al. [21] noted a recurrence rate of 45–
100% with surgery alone and less than 50% when surgery
was combined with corticosteroid injection.
Effective topical delivery of any pharmaceutical agent
requires the ability to penetrate the epidermis. Fractional
laser therapy creates precise, uniform columns of tissue
vaporization which in theory might help to facilitate drug
delivery past the epidermal barrier. Haedersdal et al. [22]
demonstrated this concept in an animal model, noting enhanced uptake of topical methyl 5-aminolevulinate after
ablative fractional laser treatment.
In this case series, we evaluated the feasibility and efficacy of same-session ablative fractional laser therapy
combined with enhanced topical corticosteroid delivery.
Potential benefits include the introduction of a simple,
cost-effective strategy to combine two valuable scar therapies and possibly create a synergistic therapeutic
response.
MATERIALS AND METHODS
Subject Population
A total of 15 consecutive subjects with hypertrophic
scars resulting from burns, surgical, or other traumatic
injuries present for at least one year were included
(Table 1). Written informed consent was obtained from
each patient. Patients were not considered for combination treatment in the setting of pregnancy, breastfeeding,
oral retinoids 6 months prior to treatment, active infection, or lesions suspicious for malignancy.
Study Design
This was a prospective case series conducted to evaluate the efficacy of fractional ablative laser followed by topical triamcinolone acetonide suspension (10 or 20 mg/ml)
as a treatment option for severe hypertrophic scars. The
chosen concentration of triamcinolone acetonide was dependent on the location and thickness of the scar. Larger
TABLE 1. Demographics and Clinical Characteristics of Each Patient
Skin
Number Age Gender type
Type of scar
Age of scar
(years)
1
2
3
42
42
28
Female
Female
Female
2
2
2
Hypertrophic burn scar
Hypertrophic burn scar
Hypertrophic burn scar
22
22
5
4
17
Female
5
Traumatic keloid scar
5
6
22
25
Female
Female
2
3
Burn scar
Acne keloid scar
21
15
7
8
9
10
11
12
13
14
15
52
42
52
22
22
28
48
23
40
Female
Female
Female
Male
Female
Female
Male
Male
Female
4
2
2
2
2
3
5
2
3
Hypertrophic burn scar
Hypertrophic burn scar
Traumatic atrophic scar
Erythematous burn scar
Mesh graft scar
Hemangioma residual scar
Acne keloid scar
Hypertrophic burn scar
Surgical scar
7
22
5
5
21
27
14
4
3
4
Laser type
Fractional ablative CO2 3
Fractional ablative CO2 3
Fractional ablative CO2,
fractional non-ablative 3
Shave excision and fractional
ablative CO2 3
Fractional ablative CO2 3
Shave excision and fractional
ablative CO2 3
PDL and fractional ablative CO2 4
Fractional ablative CO2 3
PDL and fractional ablative CO2 3
PDL and fractional ablative CO2 3
Fractional ablative CO2 3
Fractional ablative CO2 2
Fractional ablative CO2 4
Fractional ablative CO2 3
Fractional ablative CO2 3
Kenalog
strength (mg)
10
10
20
10
10
10
10
10
10
10 and 40
10
10
10
20
10
TREATMENT OF HYPERTROPHIC SCARS
scars in locations of thicker skin, such as the back, would
generally receive 20 mg/ml, while scars with a lesser
degree of hypertrophy on thinner skin would receive
10 mg/ml. Each subject received a course of three to five
combination treatments at 2- to 3-month intervals. Anesthesia was achieved with a topical anesthetic gel containing 20% benzocaine, 8% lidocaine, and 4% tetracaine for
1–2 hours prior to the procedure. This was followed by
fractional ablative carbon dioxide (CO2) laser treatment
(Ultrapulse Encore, Deep FX, Lumenis, Inc., Yokneam,
Israel) over the entire scar sheet. Three of the patients
also received pulsed dye laser treatment for erythema prior to the fractional treatment. Settings were customized
for each patient at each treatment session according to
estimated scar thickness. Pulse energies ranged from 12.5
to 20 mJ at a treatment density of 10–15%. Within
2 minutes of fractional laser treatment, a thin layer of triamcinolone acetonide suspension was drizzled over the
site and rubbed gently over the ablated columns.
Post-Treatment Care
After treatment, the treatment areas were cooled with
ice packs for 10 minutes. Occlusive dressings were not applied. Patients were instructed to perform acetic acid
soaks and use a moisturizer three times a day for several
days until healed. Patients were also directed to apply a
physical sunscreen and avoid sun exposure while the
study was in progress.
Clinical Assessment
To assess scar response, three blinded observers evaluated photographs taken both at baseline and at 6 months
following the final therapy session. Photographs were
obtained using identical camera settings, lighting conditions, and patient positioning (Nikon D300, 13.1 million
total pixels, 12.3 million effective pixels). First, observers
determined which photograph was ‘‘before’’ and ‘‘after.’’
They subsequently evaluated the improvements in overall
appearance, dyschromia, degree of hypertrophy, and texture using a quartile scale. The following four-point scale
was utilized: 0 for <25% improvement, 1 for 25–50% improvement, 2 for 50–75% improvement, 3 for >75% improvement. In no case did the observer order the before
and after photographs incorrectly. For each patient,
scores in each category were averaged to assign an overall
score.
137
Fig. 1. Average improvement scoring for overall, texture,
dyschromia, and hypertrophy as determined by three blinded
investigators at 6 months post-treatment.
overall improvement score by a subject was 3.00, which
11 of 15 patients attained (Fig. 2).
Texture
Of the 15 patients with hypertrophic scars, 12 patients
received the highest possible texture improvement score
of 3.00 by all blinded observers. The remaining three
patients obtained an average improvement between 2.00
and 2.49. The range for average texture improvement was
between 2.33 and 3.00. The mean improvement in texture
was 2.84.
Hypertrophy
The mean improvement for scar hypertrophy was 2.76
with a range from 1.67 to 3.00. Eleven patients earned an
average score of 3.00 out of 3.00. One patient received an
average score of 1.50–1.99, two patients an average score
of 2.00–2.49, and one patient a score of 2.50–2.99.
Dyschromia
The average improvement score for dyschromia was
2.36, with a range of 0.67–3.00. One patient earned a
score between 0.50 and 0.99. One earned a score between
1.00 and 1.49, six between 2.00 and 2.49 and seven subjects earned the highest score of 3.00.
RESULTS
The observers accurately determined the pre- and postphotographs 45 out of 45 times. Of the four improvement
parameters measured, texture received the highest improvement score, while dyschromia displayed the least
numeric improvement. Each category assessed achieved
an average improvement of greater than 2, corresponding
to an improvement of greater than 50% (Fig. 1).
Overall
The overall average score assessed by the three-blinded
observers was 2.73 on a 0–3 scale. The highest average
Fig. 2. Overall response to treatment averaged by three
blinded investigators at 6 months post-treatment.
138
WAIBEL ET AL.
Fig. 3. Before and 6 months after Laser Assisted Delivery
Systems Treatment using triamcinolone acetonide for
hypertrophic burn scar. A: Twenty-eight-year-old female
(patient number 3 in Table 1) patient at initial presentation
of a 5-year-old hypertrophic contracture scar sustained from
house fire. Patient had severely decreased range of motion in
wrist joint. Treated with three treatments of non-ablative
fractional followed by two treatments of ablative fractional
laser 20 mJ with 10% density and topical triamcinolone
acetonide 20 mg/ml immediately after the fractional ablative
laser. B: Six months after five laser and triamcinolone acetonide sessions showing decrease in hypertrophy and improvement of dyschromia. Patient also reported increased range of
motion in wrist doing activities of daily life.
Most subjects experienced mild to moderate erythema
and edema immediately post-treatment; no subjects experienced severe pain, erythema or edema after any treatment. Treatments were well-tolerated and no adverse
effects were reported (Figs. 3–5).
DISCUSSION
Treatment of severe cutaneous scars can be complex
and often requires a multimodal approach to therapy.
Intralesional corticosteroids have been a mainstay in the
treatment of hypertrophic scars for decades, leading to
improvements through a variety of mechanisms including
Fig. 4. Before and 6 months after Laser Assisted Delivery
Systems Treatment using triamcinolone acetonide for hypertrophic mesh graft scar. A: Twenty-two-year-old female
(patient number 11 in Table 1) after burn fire in home as a
child. Acute therapy included debridement and mesh graft at
time of injury as a toddler. Photo is during initial consultation for erythematous, hypertrophic burn scar. Scar was
21 years old at the time of consultation. Patient underwent
three treatments of fractional ablative laser 15 mJ with 15%
density followed by topical triamcinolone acetonide 10 mg/ml
immediately after the fractional ablative laser. B: Six months
after three fractional ablative laser treatments and triamcinolone acetonide with decreased erythema and improved
texture. Mesh graft pattern smoother after laser and triamcinolone acetonide treatment.
diminished collagen synthesis and increased collagen degradation [20]. The advent of fractional laser technology
within the last decade has significantly increased potential treatment options for patients with disfiguring and
disabling scars [15–18]. The results of our series indicate
that combination same-session therapy with laser and
laser-assisted delivery of triamcinolone acetonide offers
TREATMENT OF HYPERTROPHIC SCARS
Fig. 5. Before and 6 months after Laser Assisted Delivery
Systems Treatment using triamcinolone acetonide. A:
Twenty-five-year-old female (patient number 6 in Table 1)
developed spontaneous keloid scars in central chest during
puberty after acne eruption. No prior treatment. Patient had
pruritus and pain with keloid. Patient underwent three
fractional ablative laser treatments 17.5 mJ with 10%
density followed by topical triamcinolone acetonide 10 mg/ml
immediately after the fractional ablative laser. Lower right
and left periphery of scars had shave excision. B: Six months
after laser and triamcinolone treatments with flattening of
scar. Some tension remains in the central zone which may be
addressed with z-plasty surgical reconstruction.
efficient, safe, and effective treatment of challenging hypertrophic cutaneous scars. Various aspects of scar assessment such as texture, hypertrophy, and dyschromia
were all positively impacted by combination therapy.
Ablative fractional laser-assisted corticosteroid delivery
may take advantage of the newly formed channels to penetrate uniformly and deeply into dermal scars. Furthermore, injection of triamcinolone acetonide is often painful
and consistent dosing is difficult to achieve throughout
the scar. In contrast, topical application of triamcinolone
acetonide after fractional resurfacing is painless and may
be applied with greater uniformity. To our knowledge,
this is the first case series in the literature evaluating the
efficacy of this combination technique in the treatment of
hypertrophic scars.
While the results of this series are promising, there
are significant limitations that must be considered. The
lack of a control makes it impossible to ascribe synergistic benefits to the combination treatment over the individual treatments alone. However, the results of this
series compare favorably with the experience of the
139
authors in both the rapidity and degree of improvement
over the individual modalities. Further investigation including prospective controlled trials will certainly be
required to determine if same-session combination fractional laser and topical corticosteroid therapy is more
effective compared to either modality alone, as well as to
determine other variables such as optimal laser settings
and drug dosing.
One exciting potential application of fractional ablative
laser technology is the ability to deliver drugs and other
bioactive agents to patients via channels of a predetermined depth into cutaneous tissue. Current ablative fractional laser devices have a significant benefit in being
tunable and thus creating channels of a predetermined
depth and density. Previous histologic studies in normal
skin have documented complete re-epithelialization within 48 hours after ablative fractional CO2 laser treatment
[23]. The preference of the authors is to apply the triamcinolone within 2 minutes of fractional treatment at the
earliest phases of the inflammatory cascade. Capillary action likely facilitates the passage of the triamcinolone acetonide suspension through the channels without the need
for an occlusive dressing. We have termed this mode of
delivery laser assisted delivery systems, or LADS. While
this study utilizes triamcinolone acetonide as the agent
taking advantage of the microscopic treatment zones created by the laser, this technique holds promise not only
for scar treatment but for a multitude of disorders using
cell and drug based approaches.
REFERENCES
1. Klein MB, Donelan MB, Spence RJ. Reconstructive surgery.
J Burn Care Res 28: 2007; 602–606.
2. Kwon SD, Kye YC. Treatment of scars with a pulsed Er:YAG
laser. J Cutan Laser Ther 2: 2000; 27–31.
3. Liu A, Moy RL, Ozog DM. Current methods employed in the
prevention and minimization of surgical scars. Dermatol
Surg 37: 2011; 1740–1746.
4. Sawcer D, Lee HR, Lowe NJ. Lasers and adjunctive treatments for facial scars: A review. J Cutan Laser Ther 1: 1999;
77–85.
5. Butz M, Conrady D, Baumgartler H, Mentzel HE. [Rehabilitation of burn victims. A difficult path back to normality].
MMW Fortschr Med 144: 2002; 32–34.
6. Harries CA, Pegg SP. Measuring pressure under burns pressure garments using the Oxford Pressure Monitor. Burns 15:
1989; 187–189.
7. Carr-Collins JA. Pressure techniques for the prevention of
hypertrophic scars. Clin Plast Surg 19: 1992; 733–743.
8. Berman B, Viera MH, Amini S, Huo R, Jones IS. Prevention
and management of hypertrophic scars and keloids after
burns in children. J Craniofac Surg 19: 2008; 989–1006.
9. Alster TS, Williams CM. Treatment of keloid sternotomy
scars with 585 nm flashlamp-pumped pulsed-dye laser. Lancet 345: 1995; 1198–1200.
10. Nouri K, Rivas MP, Stevens M, Ballard CJ, Singer L, Ma F,
Vejjabhinanta V, Elsaie ML, Elgart GW. Comparison of the
effectiveness of the pulsed dye laser 585 nm versus 595 nm
in the treatment of new surgical scars. Lasers Med Sci 24:
2009; 801–810.
11. Bouzari N, Davis SC, Nouri K. Laser treatment of keloids
and hypertrophic scars. Int J Dermatol 46: 2007; 80–88.
12. Alster TS. Improvement of erythematous and hypertrophic
scars by the 585-nm flashlamp-pumped pulsed dye laser.
Ann Plast Surg 32: 1994; 186–190.
13. Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR.
Fractional photothermolysis: A new concept for cutaneous
140
14.
15.
16.
17.
18.
WAIBEL ET AL.
remodeling using microscopic patterns of thermal injury.
Lasers Surg Med 34: 2004; 426–438.
Waibel J, Beer K, Narurkar V, Alster T. Preliminary
observations
on
fractional
ablative
resurfacing
devices: Clinical impressions. J Drugs Dermatol 8: 2009;
481–485.
Waibel J, Beer K. Ablative fractional laser resurfacing for
the treatment of a third-degree burn. J Drugs Dermatol 8:
2009; 294–297.
Kwan JM, Wyatt M, Uebelhoer NS, Pyo J, Shumaker PR.
Functional improvement after ablative fractional laser treatment of a scar contracture. PM R 3: 2011; 986–987.
Cho SB, Lee SJ, Chung WS, Kang JM, Kim YK. Treatment
of burn scar using a carbon dioxide fractional laser. J Drugs
Dermatol 9: 2010; 173–175.
Waibel J, Wulkan AJ, Lupo M, Beer K, Anderson RR. Treatment of burn scars with the 1,550 nm nonablative fractional
erbium laser. Lasers Surg Med 2012.
19. Qu L, Liu A, Zhou L, He C, Grossman PH, Moy R, Mi QS,
Ozog D. Clinical and molecular effects on mature burn scars
after treatment with a fractional CO2 laser. Lasers Surg
Med 2012;44:517–524.
20. Kiil J. Keloids treated with topical injections of triamcinolone acetonide (kenalog). Immediate and long-term results.
Scand J Plast Reconstr Surg 11: 1977; 169–172.
21. Mustoe TA, Cooter RD, Gold MH, Hobbs FD, Ramelet AA,
Shakespeare PG, Stella M, Teot L, Wood FM, Ziegler UE.
International clinical recommendations on scar management. Plast Reconstr Surg 110: 2002; 560–571.
22. Haedersdal M, Sakamoto FH, Farinelli WA, Doukas AG,
Tam J, Anderson RR. Fractional CO(2) laser-assisted drug
delivery. Lasers Surg Med 42: 2010; 113–122.
23. Hantash B, Bedi VP, Kapadia B, Rahman Z, Jiang K, Tanner
H, Chan KF, Zachary CB. In vivo histological evaluation of a
novel ablative fractional resurfacing device. Lasers Surg
Med 2007;39(2):96–107.